Smith, B. D., Lachowiez, C. A., Ambinder, A. J., Binder, G., Angiolillo, A., Potluri, R., … LeBlanc, T. W. (2024). Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax. In Blood (Vol. 144, pp. 2855–2855). American Society of Hematology. https://doi.org/10.1182/blood-2024-210603

Smith, B Douglas, Curtis A. Lachowiez, Alexander J. Ambinder, Gary Binder, Anne Angiolillo, Ravi Potluri, Eros Papademetriou, and Thomas W. LeBlanc. “Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax.” In Blood, 144:2855–2855. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-210603.

Smith BD, Lachowiez CA, Ambinder AJ, Binder G, Angiolillo A, Potluri R, et al. Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax. In: Blood. American Society of Hematology; 2024. p. 2855–2855.

Smith, B. Douglas, et al. “Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 2855–2855. Crossref, doi:10.1182/blood-2024-210603.

Smith BD, Lachowiez CA, Ambinder AJ, Binder G, Angiolillo A, Potluri R, Papademetriou E, LeBlanc TW. Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax. Blood. American Society of Hematology; 2024. p. 2855–2855.